NuSirt also announced the start of enrollment for its Phase 2A clinical trial targeting this disease at nine U.S. research sites. NuSirt Biopharma president and executive chairman of
In an article for Arena International’s Clinical Trial Year Book 2016, Adam Dion, GlobalData’s Senior Healthcare Industry Analyst, says that while the pharmaceutical outsourcing services sector has seen
The acceptance of the NDA by the FDA in its 74-day letter indicates that the application permits a substantive review and there are no issues that have been
CAT-2054 is an oral small molecule that modulates the SREBP pathway. SREBP is a master regulator of lipid metabolism that impacts LDL, triglycerides and glucose with the potential
STARTRK-NG (which stands for "Studies of Tumor Alterations Responsive to Targeting Receptor Kinases – Next Generation") is a multicenter, open label, dose-escalation and expansion study designed to determine
The Company plans to use the proceeds from the financing to advance its pipeline of direct tumor targeting and immuno-stimulatory epigenetic inhibitors, which includes its two wholly-owned, clinical-stage
The Federal Commission for the Protection against Sanitary Risks (COFEPRIS) has approved Dengvaxia, tetravalent dengue vaccine, for the prevention of disease caused by all four dengue virus serotypes
The agreement creates opportunities for scientists at Princeton University and Bristol-Myers Squibb to collaborate on top-flight synthetic chemistry research, leveraging the two sites’ close proximity to foster a
Celldex previously announced the collaboration with Roche to evaluate the novel immunotherapy combination in March 2015. Under the terms of the agreement, Roche will provide atezolizumab, and Celldex
In each of these collaborations, Adimab will use its proprietary yeast-based discovery platform to generate IgGs for development as therapeutic products. MD Anderson and Memorial Sloan Kettering retain
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.